Teva Pharmaceutical Industries (TEVJF) Gross Profit (2016 - 2026)

Teva Pharmaceutical Industries has disclosed Gross Profit across 11 years of filings, most recently posting $2.0 billion for Q1 2026.

• Quarterly Gross Profit rose 5.06% year-over-year to $2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 billion (up 10.58% YoY) and the FY2025 annual result came in at $8.9 billion, up 10.84% from the prior year.
• Gross Profit slipped to $2.0 billion in Q1 2026, from $2.7 billion in the prior quarter.
• Over five years, Gross Profit peaked at $2.7 billion in Q4 2025 and troughed at $1.6 billion in Q1 2023.
• A 5-year average of $2.0 billion and a median of $1.9 billion in 2025 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit decreased 13.66% — and 2023, when it jumped 36.5%.
• Tracing TEVJF's Gross Profit over 5 years: stood at $1.8 billion in 2022, then surged by 36.5% to $2.4 billion in 2023, then declined by 12.21% to $2.1 billion in 2024, then rose by 25.22% to $2.7 billion in 2025, then retreated by 25.75% to $2.0 billion in 2026.
• Business Quant data shows TEVJF's Gross Profit at $2.0 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.3 billion in Q3 2025.